OsteoRemedies recently announced that it has received FDA clearance for its Remedy Spectrum GV hip spacer system and Spectrum GV bone cement.
The system is designed to give surgeons a broad spectrum of treatment options with both Gentamicin and Vancomycin.
“We are very proud to have the first FDA cleared dual-antibiotic spacer system and bone cemetery offering,” Chris Hughes, president and CEO of OsteoRemedies, said in a press release. “Since we started the company in 2013, our commitment to the growing problem of treating joint infections has been our mission. The amount of science, testing and clinical data supporting this launch is unparalleled in our space. The addition of the Spectrum GV portfolio, further enhances our vision for providing simple solutions for complex disorders for revision infection remedies and achieving a market leadership position in our niche.”
The company is launching the Spectrum GV system Nov. 1-4 at the American Academy of Hip and Knee Surgeons in Dallas.
